Flagship unveils gut-focused upstart Kintai, with former GSK exec as chief
Prolific venture group Flagship Pioneering has spawned a fresh biopharma player with a former big pharma exec at the helm: Kintai Therapeutics. The Cambridge, Massachusetts-based company is focusing on the gut — but it is not limiting itself to microbiota and looking instead at the interplay between microbes, immune cells, and neurons in the region, to harness a new class of therapeutics.
“The gut—which is home to trillions of bacteria, 70% of our immune cells, and 500 million neurons—is truly a command center, transmitting constant messages and signals throughout the body that affect our propensity for disease,” said David Berry, general partner at Flagship Pioneering and co-founder of Kintai Therapeutics in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.